4//SEC Filing
Birznieks Gunther 4
Accession 0001209191-23-016460
CIK 0001347178other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 6:24 PM ET
Size
7.7 KB
Accession
0001209191-23-016460
Insider Transaction Report
Form 4
Birznieks Gunther
SVP, Business Development
Transactions
- Sale
Common Stock
2023-03-02$6.20/sh−8,509$52,793→ 214,248 total - Sale
Common Stock
2023-03-03$6.26/sh−8,268$51,791→ 205,980 total
Footnotes (3)
- [F1]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.1901 to $6.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2301 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeother
Related Parties
1- filerCIK 0001702031
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 6:24 PM ET
- Size
- 7.7 KB